Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance

Merck & Co., Inc.Trade
Vanguard Tax Managed Fund FTSE Developed Markets ETFTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Merck & Co., Inc. trades at $131.98 (market cap $321.77B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.37. The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none. Which is the better fit depends on your goals.

MRKVEA
Market Cap
$321.77B
Sector
Health
52-Week High
$131.84$72.89
52-Week Low
$77.60$58.19
Enterprise Value
$368.53B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Vanguard Tax Managed Fund FTSE Developed Markets ETF

VEA trades at $73.31, up 1.12% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with both new acquisitions and position reductions. Recent news highlights VEA's competitive advantages in expense ratios and international diversification compared to peers like SPGM and NZAC.

Outlook remains positive given strong technical momentum and cost advantages, though overbought RSI signals near-term caution. Key risks include international market volatility and currency fluctuations. The ETF's low-cost structure and developed market exposure provide long-term diversification benefits for US investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Vanguard Tax Managed Fund FTSE Developed Markets ETF

The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VEA